Welcome to the Team FIS 26.2 with Donna Fundraising Page!
FIS is very excited to be partnering with the 26.2 with DONNA to help raise funds for ground breaking breast cancer research and to empower women living with breast cancer. With more than $1.2 million in contributions from 26.2 with DONNA, Mayo Clinic has established the Breast Cancer Translational Genomics Program. Under the direction of Dr. Edith Perez, M.D., Mayo researchers are working hard to finish breast cancer.
The team has created one of the first templates for translating each patient’s genome information into meaningful clues that will help individualize all aspects of breast cancer care including diagnosis, prognosis, and treatment.
To date, the research team has identified and experimentally validated 56 gene mutations that have never been identified in the setting of breast cancer. And as reported in the April 15, 2012 issue of Cancer Research, Mayo researchers have just discovered a new class of molecular mutation in various forms of breast cancer, a finding that may shed new light on development and growth of different types of breast tumors. Called fusion transcripts, the mutated forms of RNA may also provide a way to identify tumor subtypes and offer new strategies to treat them. This study is the first to systematically search for fusion genes and fusion transcripts linked to different types of breast tumors.
The Mayo Clinic Research team has also discovered a drug used to treat blood cancers may also stop the spread of invasive breast cancer. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.
"Treatment with low doses of decitabine in an animal model of breast cancer restored PRKD1 expression, reduced tumor size, and blocked metastasis to the lung," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic in Florida.
"The outcome of patients with invasive breast cancer is less than optimal despite many attempts to improve treatment, including advanced chemotherapy and hormonal therapy," says Dr. Storz. "We hope this study offers a new avenue to prevent breast cancer from becoming aggressive and untreatable."
Copyright © 2014. 26.2 With Donna The National Marathon To Finish Breast Cancer